Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

Questions for Deliberation: June 30, 2017 Public Meeting

Clinical Evidence

1. For postmenopausal women with osteoporosis and a high risk of fracture,¹ is the evidence adequate to demonstrate that the net health benefit of treatment with teriparatide (Forteo®, Eli Lilly and Co.), is greater than that of treatment with zoledronic acid?
   Yes No

2. For postmenopausal women with osteoporosis and a high risk of fracture,¹ is the evidence adequate to demonstrate that the net health benefit of treatment with abaloparatide (Tymlos™, Radius Health Inc.), is greater than that of treatment with zoledronic acid?
   Yes No

3. For postmenopausal women with osteoporosis and a high risk of fracture,¹ is the evidence adequate to distinguish between the net health benefit of teriparatide and abaloparatide?
   Yes No

Long-term Value for Money

4. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with teriparatide followed by zoledronic acid versus treatment with zoledronic acid alone for postmenopausal women with osteoporosis at high risk for fracture?¹
   a. Low       b. Intermediate     c. High

5. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with abaloparatide followed by zoledronic acid versus treatment with zoledronic acid alone for postmenopausal women with osteoporosis at high risk for fracture?¹
   a. Low       b. Intermediate     c. High

¹Per the US Food and Drug Administration (FDA) labeled indication for the anabolic agents, high risk for fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or an intolerance to or failure of other available osteoporosis therapy.